Health and medicine — advanced

The B2 lesson covered everyday medical vocabulary: chronic vs acute, depression/anxiety/PTSD, preventive care, the basic US healthcare system, telemedicine. By C1 you have those. The C1 layer is the clinical register — the language used in medical literature, regulatory filings, healthcare-policy debate, and bioethics. This register has its own diction (Latinate over everyday), its own genres (case report, retrospective cohort, meta-analysis, forest plot), its own regulatory vocabulary (IND, NDA, BLA, REMS), its own policy vocabulary (PPO, ACO, capitation, prior authorization), and its own ethical vocabulary (informed consent capacity, futile care, Tarasoff, EMTALA).

This lesson focuses on the registers that operate at the intersection of medicine and policy / law / ethics. We assume the B2 everyday vocabulary.

Latinate vs everyday clinical vocabulary

The fundamental register split in medical English is between Latinate clinical terms (used in charts, between clinicians, in publications) and everyday equivalents (used in patient communication and lay press). A C1 reader of medical literature must recognize both columns.

The Latinate column is the register of charts, clinical notes, and medical literature. The everyday column is the register of patient education and lay press. Clinicians slide between the two depending on audience — a doctor uses MI with another doctor, heart attack with a patient, and either with a knowledgeable family member.

A C1 reader of medical literature should recognize the Latinate forms without translation. A C1 speaker in a clinical context (patient, family member, journalist) should be able to translate to the everyday register as needed.

Medical literature reading — NEJM / JAMA / The Lancet

The major peer-reviewed medical journals (New England Journal of Medicine, JAMA, The Lancet, BMJ) publish a relatively small set of study types, each with its own structure and vocabulary.

Study types

• Case report — single patient or small case series; lowest level of evidence; useful for rare presentations or novel diagnoses.
• Case-control study — retrospective; compares people with a condition (cases) to people without (controls); useful for rare conditions.
• Cross-sectional study — snapshot of a population at one point in time; describes prevalence, not causation.
• Cohort study — follows a defined group over time; can be prospective (forward-looking) or retrospective (chart review).
• Retrospective cohort — uses existing records to follow a cohort backward in time.
• Randomized controlled trial (RCT) — gold standard of clinical research; subjects randomly assigned to treatment or control.
• Double-blind RCT — neither subjects nor investigators know assignment; reduces bias.
• Placebo-controlled — uses inactive comparator.
• Active-comparator — compares against existing standard treatment (not placebo); ethical requirement when withholding treatment would harm.
• Pragmatic trial — designed to test effectiveness in real-world conditions, not just efficacy under ideal conditions.
• Systematic review — comprehensive review following PRISMA methodology.
• Meta-analysis — statistical pooling across multiple studies.

Statistical and methodological vocabulary

• Primary endpoint vs secondary endpoint — the main outcome the trial is powered to detect vs additional outcomes.
• Powered to detect — the trial has sufficient sample size to find a specified effect with adequate statistical power.
• Intention-to-treat (ITT) vs per-protocol (PP) analysis — analyzing everyone randomized regardless of completion vs only those who completed the protocol.
• Hazard ratio (HR) — relative risk of an event in treatment vs control over time.
• Odds ratio (OR) — odds of an outcome in exposed vs unexposed.
• Number needed to treat (NNT) — how many patients must be treated for one to benefit.
• Number needed to harm (NNH) — same, for harm.
• Confidence interval (CI) — the range within which the true effect likely falls; usually 95% CI.
• p-value — probability the observed result occurred under the null hypothesis; the conventional threshold is p < 0.05.
• Statistical significance vs clinical significance — a result can be statistically significant but trivially small clinically (especially with large samples). One of the most common literature-reading pitfalls.
• p-hacking — running multiple analyses until finding one with p < 0.05; a methodological criticism.
• Multiple comparisons problem — running many tests increases false-positive rate; addressed via Bonferroni correction, FDR control, etc.
• HARKing — Hypothesizing After Results are Known; presenting a post-hoc finding as a prior hypothesis.
• Pre-registration — depositing the study protocol publicly before running it; counters p-hacking and HARKing.
• Effect size — magnitude of effect (Cohen’s d, R², HR, etc.); distinct from p-value.
• Heterogeneity — variation across studies in a meta-analysis; I² statistic quantifies it.
• Forest plot — the visual summary of a meta-analysis showing each study’s effect and the pooled estimate.
• Funnel plot — visual check for publication bias.
• Publication bias — positive results more likely to be published than null results; distorts meta-analysis.

Critical-reading vocabulary

• External validity / generalizability — does the trial’s result apply to populations beyond the studied one?
• Internal validity — does the trial measure what it claims to measure?
• Selection bias — systematic differences in who is included.
• Confounding — a third variable explaining the apparent association.
• Reverse causation — outcome causes the exposure rather than the other way.
• Surrogate endpoint — proxy measure (e.g., LDL cholesterol for heart disease) that may not track the clinical outcome.
• Hard endpoint — actual clinical outcome (death, MI, stroke) vs surrogate.

FDA regulatory pathway

The vocabulary of US drug and device approval is dense and recurs in healthcare journalism.

Drug approval

• IND (Investigational New Drug) — application allowing clinical trials in the US.
• NDA (New Drug Application) — application for FDA approval of a new chemical entity.
• BLA (Biologics License Application) — equivalent of NDA for biologic drugs (antibodies, vaccines, cell therapies).
• ANDA (Abbreviated New Drug Application) — application for a generic drug.
• 505(b)(2) — hybrid pathway for modifications of approved drugs.
• OTC monograph — Over-the-Counter drug under a standing monograph rather than NDA.

Phases of clinical trials

• Phase 1 — first-in-human, primarily safety; usually 20-100 healthy volunteers (or patients for oncology).
• Phase 2 — efficacy signal, dose-finding; hundreds of patients.
• Phase 2a / 2b — proof-of-concept vs pivotal dose-finding.
• Phase 3 — pivotal efficacy and safety; thousands of patients; basis for NDA/BLA approval.
• Phase 4 — post-marketing surveillance, post-approval studies.

Special approval pathways

• Breakthrough Therapy Designation — for drugs treating serious conditions with preliminary evidence of substantial improvement; accelerates review.
• Fast Track — designation for drugs filling unmet medical need; faster review, rolling submission.
• Accelerated Approval — approval based on surrogate endpoint reasonably likely to predict clinical benefit; requires confirmatory trial.
• Priority Review — six-month review timeline vs ten months for standard review.
• Orphan Drug Designation — for rare disease (< 200,000 US patients); tax credits, exclusivity, FDA support.
• PDUFA date — Prescription Drug User Fee Act target action date for FDA decision.

Post-approval

• REMS (Risk Evaluation and Mitigation Strategy) — required risk-management program for higher-risk drugs (e.g., isotretinoin’s iPLEDGE).
• Black box warning — boxed warning in labeling for the most serious adverse effects.
• Off-label use — use for indications not on the approved label; legal for clinicians but not for manufacturer promotion.
• PMS (Post-marketing surveillance) — ongoing safety monitoring after approval.
• MAUDE database — FDA’s Manufacturer and User Facility Device Experience reporting database.

Healthcare policy lexicon

The US healthcare system has a vocabulary as elaborate as any policy domain in American discourse.

Insurance plan types

• HMO (Health Maintenance Organization) — closed network, requires PCP gatekeeping, referrals for specialists, lowest premiums, narrowest provider choice.
• PPO (Preferred Provider Organization) — broader network, no referrals needed, higher premiums, more flexibility.
• EPO (Exclusive Provider Organization) — like PPO but no out-of-network coverage at all.
• POS (Point of Service) — hybrid; PCP gatekeeping but with out-of-network option.
• HDHP (High Deductible Health Plan) — high deductible (often $1,500+); usually paired with HSA.
• HSA (Health Savings Account) — tax-advantaged savings for medical expenses, requires HDHP.
• FSA (Flexible Spending Account) — tax-advantaged use-it-or-lose-it medical savings.

Payment models

• Fee-for-service (FFS) — pay per service rendered; the traditional model; criticized for incentivizing volume.
• Capitation — fixed per-patient payment to provider; provider bears utilization risk.
• Value-based care (VBC) — payment tied to outcomes and quality rather than volume.
• Bundled payments — fixed payment for an episode of care across providers.
• Shared savings — provider keeps part of savings if they deliver care under target cost while meeting quality.
• Risk-bearing arrangement — provider takes on financial risk for population outcomes.

Organizational models

• ACO (Accountable Care Organization) — provider network with shared accountability for a population; ACA-era Medicare model.
• PCMH (Patient-Centered Medical Home) — primary care model emphasizing care coordination.
• DSO (Dental Service Organization) / MSO (Management Services Organization) — practice-management entities supporting clinical groups.

Utilization management vocabulary

• Prior authorization (PA) — insurer pre-approval required for a service; widely criticized for administrative burden.
• Step therapy — insurer requires trying cheaper treatments before approving expensive ones.
• Formulary — covered drug list.
• Tier — formulary level (preferred generic, preferred brand, non-preferred, specialty).
• Coinsurance — patient’s percentage share of cost after deductible.
• Copay — fixed dollar amount per service.
• Deductible — amount patient pays before insurance kicks in.
• OOP max (out-of-pocket maximum) — annual cap on patient cost-share.
• In-network vs out-of-network — providers under insurer contract vs not.
• Balance billing — out-of-network provider billing patient for difference between insurer payment and full charge. The No Surprises Act (2022) restricts this for emergency and certain other care.
• MLR (Medical Loss Ratio) — percentage of premium spent on care vs administration; ACA mandates minimum MLR.

Government programs

• Medicare — federal program for 65+ and certain disabilities (Parts A, B, C/Advantage, D).
• Medicaid — federal-state program for low-income (varies by state expansion under ACA).
• CHIP — Children’s Health Insurance Program.
• Tricare — military health program.
• VA — Veterans Affairs healthcare.
• IHS — Indian Health Service.
• Marketplace / Exchange — ACA-established individual insurance market.
• Subsidies / APTC — Advance Premium Tax Credit; income-based ACA premium support.
• Medigap — supplemental private insurance for Medicare beneficiaries.
• Dual eligibles — beneficiaries of both Medicare and Medicaid.

Bioethics — the working vocabulary

A C1 reader of medical journalism, regulatory debate, and end-of-life discussions encounters specific bioethics vocabulary regularly.

Consent and decision-making

• Informed consent — agreement to treatment after disclosure of risks, benefits, alternatives.
• Capacity — the patient’s ability to understand and decide; distinct from competency (legal).
• Decisional capacity — clinical assessment of capacity for a specific decision.
• Surrogate decision-maker / proxy — person legally authorized to decide for an incapacitated patient.
• Healthcare proxy / healthcare power of attorney — legal document naming a surrogate.
• Advance directive — document specifying preferences in advance (living will + healthcare proxy).
• Living will — directive specifying treatment preferences.
• DNR (Do Not Resuscitate) — order to forgo CPR.
• DNI (Do Not Intubate) — order to forgo intubation.
• POLST / MOLST — Physician Orders for Life-Sustaining Treatment; portable directives.

End-of-life vocabulary

• Palliative care — symptom management and quality-of-life focus, regardless of prognosis.
• Hospice — end-of-life care, typically for prognosis ≤ 6 months.
• Comfort care / comfort measures only (CMO) — care focused on symptom relief, withdrawing curative measures.
• Withdrawal of care vs withholding — stopping ongoing treatment vs not starting new treatment.
• Futile care / medically futile — treatment that cannot achieve its goal; the determination is ethically and clinically contested.
• Palliative sedation — sedation to relieve suffering when other measures fail.
• Medical aid in dying (MAID) / physician-assisted dying (PAD) — physician-prescribed lethal medication that the patient self-administers; legal in 10 US states + DC.
• Death with Dignity — common state-statute name for MAID.

Special legal-ethical doctrines

• Tarasoff duty — duty to warn or protect identified third parties from a patient’s threats; from Tarasoff v. Regents of UC (1976).
• EMTALA (Emergency Medical Treatment and Active Labor Act) — federal law requiring emergency screening and stabilization regardless of ability to pay.
• HIPAA — Health Insurance Portability and Accountability Act; the privacy regulatory framework.
• Stark Law / Anti-Kickback Statute — federal laws restricting physician self-referral and inducements.
• 42 CFR Part 2 — confidentiality rules for substance-use treatment records (stricter than HIPAA).
• Goldwater Rule — APA ethical principle against psychiatrists diagnosing public figures they haven’t examined.
• Beneficence vs autonomy vs non-maleficence vs justice — the four classical bioethics principles (Beauchamp and Childress).

Common Russian-L1 problems at C1

1. Using everyday vocabulary in clinical context: writing heart attack in a clinical note instead of MI, or swelling instead of edema. The clinical register has its own diction.
2. Treating statistical significance as clinical significance: assuming a p < 0.05 result is clinically meaningful when the effect size is trivial.
3. Confusing IND, NDA, BLA: not distinguishing the three FDA application types. IND opens trials; NDA/BLA approve marketing.
4. Mixing HMO, PPO, EPO, POS: these have specific structural differences. Calling an EPO a PPO in a benefits discussion can confuse a colleague.
5. Using fired for terminations (see work-career lesson) and killed for died in clinical contexts: in medical writing the operative term is expired or died; killed implies external agency.
6. Confusing capacity (clinical) with competency (legal): a patient may have decisional capacity for some decisions and not others; competency is the legal determination.
7. Misusing DNR / DNI / CMO: these are specific orders with specific scopes. A DNR does not preclude intubation; only a DNI does.

Summary

• Clinical register vs lay register: know both columns of the Latinate / everyday vocabulary so you can read MI and produce heart attack in patient communication.
• Medical literature: recognize study types (case report, retrospective cohort, RCT, meta-analysis), endpoints (primary vs secondary, composite, surrogate vs hard), and statistics (HR, OR, NNT, p-value, effect size, p-hacking critique).
• FDA regulatory pathway: IND opens trials; NDA / BLA / ANDA / 505(b)(2) seek approval; Breakthrough / Fast Track / Accelerated / Priority / Orphan are the expedited designations; REMS and black-box warnings operate post-approval.
• Healthcare policy: HMO/PPO/EPO/POS plan types; fee-for-service vs capitation vs value-based care; ACO and PCMH organizational models; prior auth, step therapy, formulary tiers; Medicare/Medicaid/CHIP/Tricare/VA government programs.
• Bioethics: informed consent and capacity, surrogate decision-makers and advance directives, palliative care vs hospice vs comfort measures, futility, MAID, Tarasoff, EMTALA, HIPAA, the four principles (beneficence, autonomy, non-maleficence, justice).
• The C1 skill is register precision and conceptual accuracy in a vocabulary where individual word choices carry medical, legal, and ethical implications.